Ad
related to: nccn guidelines- Prescribing Information
View Prescribing Information
For XTANDI® (enzalutamide).
- XTANDI® Outcomes
Read XTANDI Patient
Reported Outcomes
- XTANDI® FAQs For HCPs
Explore FAQs for Providers & Better
Prepare Your Patients.
- Clinical Trial Data
View Clinical Data & Results
From a Pivotal Trial for XTANDI®
- Prescribing Information
Search results
Results from the WOW.Com Content Network
The National Comprehensive Cancer Network (NCCN) is an alliance of 33 [1] cancer centers in the United States, most of which are designated by the National Cancer Institute (one of the U.S. National Institutes of Health) as comprehensive cancer centers. It is a non-profit organization with offices in Plymouth Meeting, Pennsylvania.
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
The National Comprehensive Cancer Network (NCCN) suggests screening for two high risk groups. [7] Group 1 guidelines include 55–77 years of age, 30 or more pack years of smoking and has quit within the past 14 years, and are a current smoker.
A treatment guide provided by NCCN Guidelines for Patients is available, [16] while the NCCN Clinical Practice Guidelines in Oncology provides a reference for clinicians. [17] Any proposed therapeutic strategy must have minimal acute and long-term toxicities. [15]
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma ...
The American National Comprehensive Cancer Network's official guidelines list TTFields as an option for the treatment of recurrent glioblastoma, but note substantial disagreement among the members of the expert panel making this recommendation. [2] High-quality evidence for the efficacy of TTFields in oncology is limited.
The National Comprehensive Cancer Network (NCCN) guidelines recommend bilateral prophylactic mastectomy and bilateral salpingo-oophorectomy for women who are carriers of germline BRCA1/2 mutation. At the age of 35 to 40 years, or once childbearing is completed, the procedure is recommended for risk reduction purposes.
Specific screening guidelines for Cowden syndrome patients have been published by the National Comprehensive Cancer Network (NCCN). [11] Surveillance focuses on the early detection of breast, endometrial, thyroid, colorectal, renal, and skin cancer. [11] See below for a complete list of recommendations from the NCCN:
Ad
related to: nccn guidelines